Comments
FDA rejects wider use for J&J/Bayer's Xarelto
22.06.2012. | WASHINGTON (Reuters) - Johnson & Johnson said on Thursday that U.S. regulators have declined to approve a new use for its Xarelto blood clot preventer to reduce the risk of heart attacks and strokes in patients with acute coronary syndrome....
